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Possible mechanisms of retinal function recovery with the use of
cell therapy with bone marrow-derived stem cells
Possíveis mecanismos de recuperação da função da retina com uso de terapia celular
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INTRODUCTION
Stem cell therapy is not a new concept. Aftermath of thebombings in Hiroshima and Nagasaki in 1945, researchersdiscovered that bone marrow transplanted into irradia-
ted mice produced haematopoiesis(1). Haematopoietic stem
cells were first identified in 1961 and their ability to migrate
and differentiate into multiple cell types was documented(2).
Bone marrow transplants are still used today as an adjunct
therapy, which enables physicians to increase chemothe-
rapeutic doses in cancer patients(3).
Distinct stem cell types have been established from em-
bryos and identified in the fetal tissues and umbilical cord
blood (UCB) as well as in specific niches in many adult mam-
malian tissues and organs such as bone marrow (BM), brain,
skin, eyes, heart, kidneys, lungs, gastrointestinal tract, pan-
creas, liver, breast, ovaries, prostate and testis(2). All stem cells
are undifferentiated cells that exhibit unlimited self renewal and
can generate multiple cell lineages or more restricted pro-
genitor populations which can contribute to tissue homeostasis
by replenishing the cells or tissue regeneration after injuries(4).
Several investigations (Mimeault M)(4) (Ortiz-Gonzalez XR)(5)
(Trounson A)(6) have been carried out with isolated embryonic,
fetal and adult stem cells in a well-defined culture microenvi-
ronment to define the sequential steps and intracellular pa-
thways that are involved in their differentiation into the speci-
fic cell lineages. More particularly, different methods for in vitro
culture of stem cells have been developed, including the use
of cell feeder layers, cell-free conditions, extracellular matrix
(ECM) molecules such as collagen, gelatin and laminin and
diverse growth factors and cytokines(4-7).
Adult stem cells are present in most organs and tissues
such as brain, bone marrow, blood vessels, skin, teeth, and
heart. These stem cells are in the tissues that they are going to
become, an area called the “stem cell niche”(8-14). The inherent
variety of stem cells has caused much debate on what consti-
tutes a stem cell. In an ongoing effort to better classify stem
cells and to understand their patterns of gene expression such
that they might later be manipulated for gene therapies,
scientists have begun genetically mapping stem cells. In ge-
neral terms, a stem cell may be defined as an undifferentiated
cell capable of self-renewal and of giving rise to one or more
differentiated cell types(4).
BONE MARROW DERIVED STEM CELL
BM-derived SCs have been proposed as a potential source
of cells for regenerative(8-9). This was based on the assumption
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RESUMO
As células tronco derivadas da medula óssea têm sido propostas como uma
fonte em potencial de células para medicina regenerativa. No olho, a degenera-
ção de células neurais da retina são a marca de doenças difusas, como a
degeneração macular relacionada com a idade (DMRI) e a retinose pigmentar.
A medula óssea é um tecido ideal para estudar as células tronco por causa da sua
acessibilidade. Devido a estas características e a experiência do transplante de
medula óssea no tratamento de doenças hematológicas, como as leucemias,
as célulastronco derivadas da medula óssea têm se tornado a maior ferramenta
na medicina regenerativa. Essas células podem ser capazes de restaurar a
função da retina através dos seguintes mecanismos: A) diferenciação celular; B)
efeito parácrino; C) reparo do epitélio pigmentado da retina. Nesta revisão nós
descrevemos os possíveis mecanismos de recuperação da função da retina com
uso de terapia celular com células tronco derivadas da medula óssea.
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that HSCs isolated from BM are plastic and are able to “trans-
differentiate” into tissue-committed stem cells (TCSCs) for
other organs (e.g., heart, liver, or brain). Unfortunately, the
concept of SC plasticity was not confirmed in recent studies
and previously encouraging data demonstrating this pheno-
menon in vitro could be explained by a phenomenon of cell
fusion or, as postulated by our group, by the presence, of
heterogeneous populations of SCs in BM(11-12). The identifica-
tion of VSELSCs (primitive, very small, embryonic-like) in BM
supports the notion that this tissue contains a population of
primitive stem cell, which, if transplanted together with
HSCs, was able to regenerate damaged tissues in certain
experimental settings. Cells from BM could be easily and safely
aspirated. After administering local anesthesia, about 10 ml of
the bone marrow is aspirated from the iliac crest using a
sterile bone marrow aspiration needle, and mononuclear bo-
ne marrow stem cells is separated using the Ficoll density
separation method(14-17) (Figure 1). Stem cell–based therapy
has been tested in animal models for several diseases, inclu-
ding neurodegenerative disorders, such as Parkinson disease,
spinal cord injury, and multiple sclerosis. The replacement of
lost neurons that are not physiologically replaced is pivotal for
therapeutic success. In the eye, degeneration of neural cells in
the retina is a hallmark of such widespread ocular diseases as
age-related macular degeneration (AMD) and retinitis pigmen-
tosa (RP). In these cases the loss of photoreceptors that occurs
as a primary event (RP) or secondary to loss of RPE (AMD) leads
to blindness(8-9).
Bone marrow is an ideal tissue for studying stem cells
because of its accessibility and because proliferative dose-
responses of bone marrow-derived stem cells can be readily
investigated. Furthermore, there are a number of well-de-
fined mouse models and cell surface markers that allow effec-
tive study of hematopoiesis in healthy and injured mice. Be-
cause of these characteristics and the experience of bone
marrow transplantation in the treatment of hematological can-
cers, bone marrow–derived stem cells have also become a
major tool in regenerative medicine. The bone marrow harbors
at least two distinct stem cell populations: hematopoietic stem
cells (HSC) and multipotent marrow stromal cells (MSC).
1) HEMATOPOIETIC STEM CELLS (HSCS)
Hematopoietic stem cells (HSCs) are multipotent stem
cells that give rise to all the blood cell types including mye-
loid (monocytes and macrophages, neutrophils, basophils, eo-
sinophils, erythrocytes, megakaryocytes/platelets, dendritic
cells), and lymphoid lineages (T-cells, B-cells, NK-cells).
HSCs are found in the bone marrow of adults, which
includes femurs, hip, ribs, sternum, and other bones. Cells can
be obtained directly by removal from the hip using a needle
and syringe (Figure 1), or from the blood following pre-
treatment with cytokines, such as G-CSF (granulocyte colony-
stimulating factors), that induce cells to be released from the
bone marrow compartment. Other sources for clinical and
scientific use include umbilical cord blood and placenta(10-11).
In reference to phenotype, hematopoeitic stem cells are
identified by their small size, lack of lineage (lin) markers, low
staining (side population) with vital dyes such as rhodamine
123 (rhodamineDULL, also called rholo) or Hoechst 33342, and
presence of various antigenic markers on their surface, many of
which belong to the cluster of differentiation series: CD34,
CD38, CD90, CD133, CD105, CD45 and also c-kit, the receptor
for stem cell factor(12-17).
2) MULTIPOTENT MESENCHYMAL STROMAL CELLS
(MESENCHYMAL STEM CELLS)
Mesenchymal stem cells (MSCs) are progenitors of all
connective tissue cells. In adults of multiple vertebrate spe-
cies, MSCs have been isolated from bone marrow (BM) and
other tissues, expanded in culture, and differentiated into
several tissue-forming cells such as bone, cartilage, fat, muscle,
tendon, liver, kidney, heart, and even brain cells.
Accordingly to the International Society for Cellular The-
rapy(18) there are three minimum requirements for a popu-
lation of cells be classified as MSC. The first is that MSCs are
isolated from a population of mononuclear cells on the basis of
their selective adherence to the surface of the plastic of cul-
ture dishes, differing in this respect with bone marrow hema-
topoietic cells, a disadvantage of this method is a possible
contamination by hematopoietic cells and cellular hetero-
Figure 1.  Sequence of photos showing the collection of bone marrow (A) and initial separation of the
mononuclear cells using Ficoll’Hypaque gradient centrifugation (B)(C)(D).
A B
C
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A
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geneity with respect to the potential for differentiation. The
second criteria is that the expressions of CD105, CD73 and
CD90 are present, and that CD34, CD45, CD14 or CD11b,
CD79, or CD19 and HLA-DR are not expressed in more than
95% of the cells in culture. Finally, the cells can be differen-
tiated into bone, fat and cartilage(19).
APPLICATION OF BONE MARROW (BM)-DERIVED STEM
CELLS IN RETINAL DISEASES
Bone marrow (BM)-derived stem cells may be able to
restore the functioning of the retina through different mecha-
nisms: A) cellular differentiation, B) paracrine effect, and C)
retinal pigment epithelium repair.
A) CELLULAR DIFFERENTIATION
The mechanisms for SC-mediated differentiation events,
including documented functional recovery, are still under
considerable scientific debate. For adult SCs, the controversy
between transdifferentiation and fusion has still to be sol-
ved(11,14). Recently, it was reported that BMSCs are able to “trans-
differentiate” or change commitment into cells that express early
heart, skeletal muscle, neural, or liver cell markers(8-9,11,14-15). Similarly,
SCs from the BM contributed to the regeneration of infracted
myocardium. This was supported by the observations in hu-
mans that transplantation of SCs from mobilized peripheral
blood expressing the early hematopoietic CD34+ antigen led
to the appearance of donor-derived hepatocytes, epithelial
cells, and neurons(8-10). Therefore, it was initially presumed the
repair seen in damaged host tissues following SC transplan-
tation or homing was due to incorporation and transdifferen-
tiation of the BMSCs at the sites of damage. However, a number
of studies have challenged this concept, providing evidence
that BMSCs may instead incorporate into host tissues via fusion
with host cells. Intravitreally injected, lineage-negative (Lin-)
hematopoietic stem cells (HSCs) have been reported to rescue
retinal degeneration in rd1 and rd10 mice. In the study, exoge-
nous Lin- HSCs prevented retinal vascular degeneration and this
vascular rescue correlated with neuronal rescue(20). Although
this approach showed a dramatic rescue effect, there was a
limitation in that intravitreally injected bone marrow (BM)-
derived stem cells were effectively incorporated into the retina
only during an early, postnatal developmental stage, but not in
adult mice. Directly injected exogenous Lin- HSCs only targeted
activated astrocytes that are observed in neonatal mice or in an
injury-induced model in the adult(20-22).
A1) THE ROLE OF BM DERIVED MICROGLIA
Microglial activation in the retina provides an early res-
ponse against infection, injury, ischemia, and degeneration.
In retinal degeneration, activated microglia migrate into
the deeper retina with the expression of tumor necrosis
factor-α before the onset of photoreceptor cell death, sugges-
ting that microglial activation may trigger neuronal cell
death(22). On the other hand, microglia secrete neurotrophic
factors and promote photoreceptor survival in a light-induced
retinal degeneration model, and promote vascular repair in
an oxygen-induced retinopathy model(22-23).
The precise mechanisms of retinal protection by BM deri-
ved microglia remain elusive. One hypothesis is that microglia
phagocytes cellular debris and clear the degenerative envi-
ronment. Another possible mechanism is that microglia secre-
te neurotrophic factors to promote residual cell survivel(22-23).
In the light-induced retinal degeneration model, microglia
secrete nerve growth factor or ciliary neurotrophic factor and
modulate secondary neurotrophic factor expression in Muller
glia, contributing to the protection of photoreceptor cells(22-24).
B) PARACRINE EFFECT
Paracrine signaling is a form of cell signaling in which the
target cell is near (“para” = near) the signal-releasing cell.
A distinction is sometimes made between paracrine and
autocrine signaling. Both affect neighboring cells, but whe-
reas autocrine signaling occurs among the same types of cells,
paracrine signaling affects other types of (adjacent) cells.
Cells communicate with each other via direct contact (jux-
tacrine signaling), over short distances (paracrine signaling), or
over large distances and/or scales (endocrine signaling).
Some cell-to-cell communication requires direct cell-cell
contact. Some cells can form gap junctions that connect their
cytoplasm to the cytoplasm of adjacent cells. In cardiac mus-
cle, gap junctions between adjacent cells allows for action
potential propagation from the cardiac pacemaker region of
the heart to spread and coordinately cause contraction of the
heart.
Below we will mention the possible paracrine effects of
stem cells (Figure 2) and their mechanisms in accordance with
the classification proposed by Crisostomo et al. (2008)(25).
B1) INCREASED ANGIOGENESIS
First, stem cells produce local signaling molecules that
may improve perfusion and enhance angiogenesis to chroni-
cally ischemic tissue. Although the particular growth factors
contributing to this neovascular effect remain to be defined,
the list includes vascular endothelial growth factor (VEGF),
hepatocyte growth factor (HGF), and basic fibroblast growth
factor (FGF2)(2-3). VEGF is a strong promoter of angiogenesis.
Although originally associated with liver regeneration, HGF also
exerts beneficial effects on neovascularization and tissue re-
modeling. FGF2, a specific member of the FGF signaling
family is involved intimately with endothelial cell proliferation
and may be a more potent angiogenic factor than VEGF(25). When
exposed to either insult or stress, mesenchymal stem cells
(MSC) in cell culture and in vivo significantly increase release
of VEGF, HGF, and FGF2, which may improve regional blood
flow as well as promote autocrine self survival. Increased
perfusion due to the production of stem cell angiogenic
growth factor has also been associated with improved end
organ function. Further, VEGF overexpressing bone marrow
stem cells demonstrate greater protection of injured tissue
than controls. Thus, VEGF, HGF, and FGF2 may be important
paracrine signaling molecules in stem cell-mediated angio-
genesis, protection, and survival(26-30).
Figure 2.  Diagram showing the paths of the paracrine effect.
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B2) DECREASED INFLAMMATION
Stem cells appear to attenuate infarct size and injury by
modulating local inflammation When transplanted into inju-
red tissue, the stem cell faces a hostile, nutrient-deficient, inflam-
matory environment and may release substances which limit
local inflammation in order to enhance its survival. Recent
studies implicate the release of the anti-inflammatory cyto-
kine IL-10 as playing an integral role in modulating the activity
of innate and adaptive immune cells, such as dendritic cells, T
cells, and B cells. Transforming growth factor beta (TGF-β)
appears to be involved in suppression of inflammation by
stem cells. TGF-β1 plays a role in T cell suppression, and its
anti-inflammatory effect may be further potentiated by con-
comitant HGF.
Modulation of local tissue levels of pro-inflammatory cyto-
kines by anti-inflammatory paracrine factors released by stem
cells, thus, are important in conferring improved outcome
after stem cell therapy(25-31).
B3) ANTI-APOPTOTIC AND CHEMOTACTIC SIGNALING
Stem cells in a third pathway promote salvage of tenuous
or malfunctioning cell types at the infarct border zone. In-
jection of MSC into a cryo-induced infarct reduces myocardial
scar width 10 weeks later(29-30). MSCs appear to activate an anti-
apoptosis signaling system at the infarct border zone which
effectively protects ischemia-threatened cell types from
apoptosis.
Evidence also exists that both endogenous and exogenous
stem cells are able to “home” or migrate into the area of injury
from the site of injection or infusion(26,30,32-38). MSC in the bone
marrow can be mobilized, target the areas of infarction, and
differentiate into target tissue type.
Furthermore, expression profiling of adult progenitor cells
reveals characteristic expression of genes associated with
enhanced DNA repair, upregulated anti-oxidant enzymes, and
increased detoxifier systems. HGF has been observed to improve
cell growth and to reduce cell apoptosis(33).
Granulocyte colony-stimulating factor (G-CSF) has been
studied widely and promotes the mobilization of bone marrow-
derived stem cells in the setting of acute injury. This homing
mechanism may also depend on expression of stromal cell-
derived factor 1 (SDF-1), monocyte chemoattractant protein-3
(MCP-3), stem cell factor (SCF), and / or IL-8(25,32-33).
B4) BENEFICIAL REMODELING OF THE EXTRACELLULAR MATRIX
Fourth, stem cell transplantation alters the extracellular
matrix, resulting in more favorable post-infarct remodeling,
strengthening of the infarct scar, and prevention of deteriora-
tion in organ function(34-37). Acute human and murine MSC
infusion prior to ischemia improve myocardial developed pres-
sure, contractility, and compliance after ischemia/reperfusion
(I/R) injury and decrease end diastolic pressure. Similarly,
direct injection of human MSC into ischemic hearts decreased
fibrosis, left ventricular dilation, apoptosis, and increased
myocardial thickness with preservation of systolic and diastolic
cardiac function without evidence of myocardial regeneration.
MSCs appear to achieve this improved function by increasing
acutely the cellularity and decreasing production of extracellular
Table 1. Table showing clinics and experimental studies using cell therapy for retinal diseases
Type of study Type of injury or illness Route used Type and source of cells
Atsushi Otani Experimental Mice with retinal Intravitreous Adult bonemarrow-derived
et al.(18)  study in animals degenerative disease transplantation lineage-negative hematopoietic stem cells
Wang S et al.(39) Experimental Retinitis Tail vein Pluripotent bone marrow-derived
study in animals pigmentosa mesenchymal stem cells (MSCs)
Li Na & Li Xiao-rong Experimental Rat injured by Intravitreous Bone-marrow mesenchymal
 & Yuan Jia-qin(27) study in animals ischemia/reperfusion transplantation stem cells
Uteza Y, Rouillot JS, Experimental study Photoreceptor cell degeneration Intravitreous Encapsulated
Kobetz A, et al.(41) in animals  in Royal College of Surgeons rats  transplantation fibroblasts
tZhang Y, Wang W(40) Experimental study Light-damaged Subretinal Bone marrow mesenchymal
in animals retinal structure space  stem cells
Tomita M(42) Experimental study Retinas mechanically injured Intravitreous Bone marrow-derived
in animals  using a hooked needle  transplantation  stem cells
Meyer JS et al.(43) Experimental study Retinal Intravitreous Embryonic stem
in animals  degeneration transplantation  (ES) cells
Siqueira RC et al(44-45) Experimental study Chorioretinal injuries caused by Intravitreous Bone marrow-derived
in animals laser red diode 670N-M  transplantation  stem cells
Wang HC et al.(46) Experimental study Mice with laser-induced Intravitreous Bone marrow-derived
in animals  retinal injury  transplantation  stem cells
Johnson TV et al.(47) Experimental study Glaucoma Intravitreous Bone marrow-derived
in animals  transplantation  mesenchymal stem cell (MSC)
Castanheira P et al.(48) Experimental study Rat retinas submitted Intravitreous Bone marrow-derived
in animals  to laser damage transplantation  mesenchymal stem cell (MSC)
Jonas JB et al.(49) Case report Patient with atrophy of the Intravitreous Bone marrow-derived
 retina and optic nerve  transplantation  mononuclear cell transplantation
Jonas JB et al.(50) Case report 3 patients with diabetic retinopathy, Intravitreous Bone marrow-derived
age related macular degeneration  transplantation mononuclear cell transplantation
and optic nerve atrophy (glaucoma)
Siqueira RC et al. Clinical Trial 5 patients with retinitis Intravitreous Bone marrow-derived
Clinical trial.gov Phase I pigmentosa transplantation mononuclear cell transplantation
NCT01068561(51-52)
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matrix proteins such as collagen type I, collagen type III, and
TIMP-1 which result in positive remodeling and function(25,35).
B5) ACTIVATION OF NEIGHBORING RESIDENT STEM CELLS
Finally, exogenous stem cell transplantation may activate
neighboring resident tissue stem cells. Recent work demons-
trated the existence of endogenous, stem cell-like popula-
tions in adult heart, liver, brain, and kidney(33-39).
These resident stem cells may possess growth factor re-
ceptors that can be activated to induce their migration and
proliferation and promote both the restoration of dead tissue
and the improved function in damaged tissue. Mesenchymal
stem cells have also released HGF and IGF-1 in response to injury
and when transplanted into ischemic myocardial tissue may
activate subsequently the resident cardiac stem cells.
Although the definitive mechanisms for protection via
stem cells remains unclear, stem cells mediate enhanced an-
giogenesis, suppression of inflammation, and improved func-
tion via paracrine actions on injured cells, neighboring resi-
dent stem cells, the extracellular matrix, and the infarct zone.
Improved understanding of these paracrine mechanisms may
allow earlier and more effective clinical therapies(25,36-37).
C) RETINAL PIGMENT EPITHELIUM (RPE) REPAIR WITH BM
DERIVED STEM CELL
RPE dysfunction has been linked to many devastating eye
disorders, including age-related macular degeneration, and to
hereditary disorders, such as Stargardt disease and retinitis
pigmentosa(38-40). Attempts to repair the RPE include transplan-
tation of RPE cells into the subretinal space(39-44). Animal studies,
RPE transplantation in humans, and macular relocation surgery
have all shown that replacing diseased RPE with healthier RPE
can rescue photoreceptors, prevent further visual loss, and even
promote visual(45). Also, recent work on human RPE patch graft
transplantation demonstrates survival and rescue of photore-
ceptors for a substantial time after grafting and holds some
promise(38). Rescue of RPE and photoreceptors beyond the area
of donor cell distribution suggests that diffusible factors are also
involved in the rescue process. However, some problems exist,
including the ability to obtain an adequate source of autolo-
gous RPE and that homologous cells have been associated with
rejection. Fetal or adult transplanted RPE cells attach to Bruch’s
membrane with poor efficiency and do not proliferate. These
transplantation procedures are complex, associated with high
complication rates, and often result in only short-term(45).
Recently, it has been reported that the bone marrow-
derived cells regenerated RPE in two different acute injury
models(39-44,46-48).
Based on the above mentioned mechanisms, experimen-
tal and human studies with intravitreal bone-marrow derived
stem cells have begun (Table 1).
Recently, some reports demonstrated the clinical feasibi-
lity of intravitreal administration of autologous bone marrow-
derived mononuclear cells (ABMC) in patients with advanced
degenerative retinopathies(49-52). More recently, our group
conducted a prospective phase I trial to investigate the safety
of intravitreal ABMC in patients with RP or cone-rod dystro-
phy, with promising results(53-55). The history starts to be writ-
ten in this very promising therapeutic field. Welcome!
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